AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00143169
Drug: Parecoxib and placebo
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT03692715
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral or intravenous ciprofloxacin prior to shockwave lithotripsy.
Trial: NCT04655729
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Blood collection
Trial: NCT03308604
Drug: Polysiloxane Gd-Chelates based nanoparticles (AGuIX)
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three intravenous injections of AGuIX will be delivered.~The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake.~Irradiation will be performed after the second MRI.~The second injection will be followed by an MRI 4 hours later.~The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance.~Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2). The starting dose level will be 30mg/kg.
Trial: NCT03308604
Drug: Chemotherapy (cisplatin)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).
Trial: NCT00328588
Drug: YM155
RxNorm normalized name: Sepantronium bromide
DrugBank: Sepantronium (DB17062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT03835507
Drug: recombinant human erythropoietin(rhEPO)
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of erythropoietin every months (total 12 months)
Trial: NCT00215644
Drug: Matuzumab
RxNorm normalized name: Matuzumab
DrugBank: Matuzumab (DB05101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn.
Trial: NCT00215644
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.
Trial: NCT00215644
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive cisplatin 60 mg/m\^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.
Trial: NCT00469716
Drug: Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)
RxNorm normalized name: Hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02793947
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg of 0.75% ropivacaine (53.33 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
Trial: NCT02793947
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg of 0.5 mg/mL morphine sulfate (10 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
Trial: NCT02793947
Drug: 0.9% sodium chloride solution
RxNorm normalized name: Precedex 80mcg/20mL in 0.9% Sodium Chloride Solution for Injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 36.07 mL 0.9% sodium chloride solution will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
Trial: NCT01393522
Drug: Milnacipran
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then taper down as appropriate for dose.
Trial: NCT00617747
Drug: Zolmitriptan
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg Nasal Spray
Trial: NCT02876861
Drug: Neoadjuvant Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.
Trial: NCT03937544
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive lymphodepleting chemotherapies consisting of Fludarabine 25mg/m2/day IV (Day -5, Day -4, Day -3 ).
Trial: NCT04026750
Drug: Pitolisant
RxNorm normalized name: pitolisant
DrugBank: Pitolisant (DB11642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.
Trial: NCT00640406
Drug: Best Medical Treatment
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: best medical treatment for hypertension secondary to renal artery stenosis according to local standards
Trial: NCT00632645
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day
Trial: NCT00632645
Drug: Xenazine
RxNorm normalized name: Xenazine
DrugBank: Tetrabenazine (DB04844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg
Trial: NCT00632645
Drug: Tiapridal
RxNorm normalized name: tiapride
DrugBank: Tiapride (DB13025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day
Trial: NCT00741598
Drug: Galantamine-ER
RxNorm normalized name: galantamine Extended Release Oral Capsule
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Galantamine-ER 8 to 24 mg per day for 16 weeks
Trial: NCT00741598
Drug: Galantamine placebo
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Galantamine placebo 8 to 24 mg per day for 16 weeks
Trial: NCT01301079
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.
Trial: NCT01301079
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in group N (placebo) was administrated saline during surgery.
Trial: NCT00313586
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT00313586
Drug: Entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00387283
Drug: AVI-4020 Injection
RxNorm normalized name: AVI-4020
DrugBank: AVI-4020 (DB05873)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02029482
Drug: ACT-128800
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01972464
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral micronized progesterone
Trial: NCT01042392
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg Aliskiren as film-coated tablet
Trial: NCT01042392
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg was given in capsule form.
Trial: NCT01042392
Drug: Matching placebo to Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
Trial: NCT00103662
Drug: Granulocyte colony-stimulating factor plus plerixafor
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
Trial: NCT00103662
Drug: Granulocyte colony-stimulating factor plus placebo
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
Trial: NCT06212284
Drug: Citalopram 20mg
RxNorm normalized name: Escitalopram 20mg Oral tablet
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doses were delivered in gelatine capsules filled with microcrystalline cellulose.
Trial: NCT04171193
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deep anesthesia with isoflurane to achieve burst suppression pattern for more than 80% of the time for 15 minutes measured in electroencephalogram and Bi-Spectral Index
Trial: NCT04171193
Drug: Sertraline Pill
RxNorm normalized name: sertraline Pill
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients that did not respond to Isoflurane treatment, will star on sertraline to evaluate any enhancement in antidepressant efficacy after pre-treatment with isoflurane
Trial: NCT00860080
Drug: PXL01
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
Trial: NCT02775292
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03959527
Drug: zoliflodacin
RxNorm normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 3g, oral administration
Trial: NCT03959527
Drug: ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 500mg, Intra-Muscular (IM) administration
Trial: NCT00217581
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
Trial: NCT00217581
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
Trial: NCT00700024
Drug: Testim
RxNorm normalized name: Testim
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/dose7day
Trial: NCT00734461
Drug: oxycodone and naltrexone
RxNorm normalized name: oxycodone and naltrexone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone
Trial: NCT00428428
Drug: Isoproterenol
RxNorm normalized name: Isoproterenol
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ISO 0.1 microgram/ml, 8 ml/min irrigation compared to saline irrigation
Trial: NCT00070564
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00926341
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab. Pioglitazone-30 mg/day, oral, 24 weeks
Trial: NCT00926341
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab. Telmisartan- 40 mg/day, oral, 24 weeks
Trial: NCT00460239
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
Trial: NCT00460239
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
Trial: NCT01996150
Drug: bleach bath (sodium hypochlorite)
RxNorm normalized name: beach strawberry extract
DrugBank: Strawberry (DB10571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take diluted bleach bath (0.005% Sodium Hypochlorite) for 5-10 minutes twice a week for 12 weeks.
Trial: NCT00032500
Drug: Echinacea
RxNorm normalized name: Echinacea
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00412789
Drug: Patupilone
RxNorm normalized name: Patupilone
DrugBank: Patupilone (DB03010)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00411723
Drug: RTL1000 (recombinant T cell receptor ligand)
RxNorm normalized name: RTL1000
DrugBank: RTL-1000 (DB17946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.
Trial: NCT04252885
Drug: Lopinavir and Ritonavir Tablets
RxNorm normalized name: Lopinavir and Ritonavir Tablets
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As indicated in arm/group descriptions
Trial: NCT04252885
Drug: Arbidol
DrugBank: Umifenovir (DB13609)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As indicated in arm/group descriptions
Trial: NCT02170857
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This material will be used in conjunction with the ordinary surgical procedure
Trial: NCT00533221
Drug: somatotropin
RxNorm normalized name: Somatotropin
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
Trial: NCT00608218
Drug: Ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an observational study. Therefore, the physician decides about dosage according to individual needs.
Trial: NCT00003115
Drug: hydromorphone hydrochloride
RxNorm normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00770913
Drug: E3810
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg taken orally, once a day for 8 weeks.
Trial: NCT00770913
Drug: E3810
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg, taken orally, twice a day for 8 weeks.
Trial: NCT00770913
Drug: E3810
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg taken orally, twice a day for 8 weeks.
Trial: NCT01472445
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02360280
Drug: ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sedative
Trial: NCT02360280
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: sedative
Trial: NCT03130933
Drug: Amoxicillin 500 Mg
RxNorm normalized name: amoxicillin 500 MG
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The tested subgroups received a prophylactic single dose of 4 x 500 Mg Amoxicillin one hour prior the lower third molar surgery.
Trial: NCT02583022
Drug: PAC-14028 cream 1.0%
DrugBank: PAC-14028 (DB12428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT02583022
Drug: PAC-14028 cream vehicle
RxNorm normalized name: PAC-14028
DrugBank: PAC-14028 (DB12428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT02654158
Drug: Low-dose of Fuganlin Oral Liquid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day
Trial: NCT03011177
Drug: Teneligliptin
RxNorm normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: teneligliptin 20mg qd
Trial: NCT03011177
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linagliptin 5mg qd
Trial: NCT00098007
Drug: Everolimus (Certican)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00650338
Drug: 0.005% latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical ocular application
Trial: NCT04245618
Drug: neoadjuvant chemotherapy ( cisplatin - gemcitabine)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy before TURBT
Trial: NCT00271219
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily oral dosing 20-140 mg
Trial: NCT00271219
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sl daily 2-32 mg
Trial: NCT02439788
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2/day x 3 days; for patients \<12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells
Trial: NCT03848793
Drug: HS-20004
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment
Trial: NCT00531947
Drug: Selegiline Transdermal System
RxNorm normalized name: Selegiline Transdermal System
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
Trial: NCT00838383
Drug: sitaxsentan (Thelin)
DrugBank: Sitaxentan (DB06268)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
Trial: NCT00838383
Drug: sitaxsentan (Thelin)
DrugBank: Sitaxentan (DB06268)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
Trial: NCT00064077
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00064077
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00064077
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00064077
Drug: Topotecan Hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00064077
Drug: Vinorelbine Tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV